Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NEW YORK, July 31, 2017 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its third fiscal quarter ended June 30, 2017 after the market close on Tuesday, August 8, 2017. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.
| Conference Call & Webcast | |
| Tuesday, August 8th @ 5pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13665443 |
| Webcast: | http://public.viavid.com/index.php?id=125142 |
| Replays – Available through August 15, 2017 | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 13665443 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
